Compare Novo Nordisk A/S (NVO) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Southern Copper Corp — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while Southern Copper Corp trades at $201 (market cap $176.69B). The key difference: Novo Nordisk A/S and Southern Copper Corp are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| NVO | SCCO | |
|---|---|---|
Market Cap | $198.57B | $176.69B |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $219.70 |
52-Week Low | $35.29 | $102.10 |
Enterprise Value | $213.37B | $177.98B |
Dividend Yield | 4.03% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Southern Copper (SCCO) trades at $208.56, up 4.93% in the last 24 hours, with a bullish technical signal from moving averages and strong support near $205. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.99 exceeding expectations, and demonstrates high profitability with a net margin of 35.87% and ROE of 50.07%. Revenue growth is accelerating, reaching $13.42B in 2025, supported by rising copper prices and a $20.5B investment plan for production expansion.
The outlook for SCCO is positive due to strong copper demand from AI infrastructure and trade policy shifts, but risks include premium valuations (P/E of 31.29) and lower H1 2026 copper output. Analyst sentiment is mixed with a consensus price target of $154.58, below the current price, indicating caution despite institutional buying interest from firms like BlackRock and Bank of New York Mellon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
